Biotest AG更新了财务预测,预期现金流动会减少,但将维持EBIT准则。 Biotest AG updates financial forecasts, expecting lower cash flow but maintaining EBIT guidance.

德国一家保健公司Biotest AG更新了收入、现金流动和ROCE的财务预测,但将EBIT指南维持在8 000万至1亿欧元之间。 Biotest AG, a German healthcare firm, has updated its financial forecasts for revenue, cash flow, and ROCE but maintained its EBIT guidance at €80 million to €100 million. 该公司现在预计,单位数收入将出现低增长,业务现金流将出现负值,为两百万位数中位数,而ROCE预测在5-8%之间。 The company now expects a low single-digit revenue increase and a negative mid-double-digit million cash flow from operations, with ROCE projected between 5-8%. 这一更新是在2024年11月14日作出的,符合欧盟条例,并通过EQS新闻服务披露。 This update, made on November 14, 2024, complies with EU regulations and was disclosed through the EQS News service.